GlaxoSmithKline cancer therapy regimen shows efficacy in trial
13 December 2010 00:00 in Pharmaceutical Company Product News
GlaxoSmithKline has published positive data from a phase III clinical trial of a new combination therapy for previously untreated HER2-positive metastatic breast cancer.
The company has combined its drug Tykerb (lapatinib) with the commonly-used chemotherapy agent paclitaxel in order to improve survival rates among sufferers.
During the 444-patient study, it was shown that statistically significant overall survival improvements were achieved using GlaxoSmithKline's treatment compared to a placebo-based regimen, while progression-free survival rates also benefited.
GlaxoSmithKline said this adds to the growing body of evidence supporting Tykerb-based treatments among breast cancer patients.
Dr Jeffrey Bloss, vice-president and medicine development leader at GlaxoSmithKline Oncology, said: "To see an overall survival result of this magnitude is definitely encouraging and positively affirms the clinical activity that a lapatinib-based therapy can demonstrate in first-line metastatic breast cancer."
This comes in the same week that the firm published data demonstrating Tykerb's efficacy when combined with trastuzumab, in addition to standard chemotherapy.
Other news stories from 13/12/2010
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency